Skip Navigation


PEDS Advance Access originally published online on November 12, 2004
Protein Engineering Design and Selection 2004 17(10):749-758; doi:10.1093/protein/gzh085
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
17/10/749    most recent
gzh085v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Pantophlet, R.
Right arrow Articles by Burton, D.R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pantophlet, R.
Right arrow Articles by Burton, D.R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Protein Engineering, Design & Selection vol. 17 no. 10 © Oxford University Press 2004; all rights reserved

Improved design of an antigen with enhanced specificity for the broadly HIV-neutralizing antibody b12

R. Pantophlet1,2, I.A. Wilson3,4 and D.R. Burton1,2,3

1Department of Immunology, 3Department of Molecular Biology and 4Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA 92037, USA

2 To whom correspondence should be addressed. E-mail: burton{at}scripps.edu; rpanto{at}scripps.edu

In an attempt to design immunogens that elicit broadly HIV-neutralizing antibodies, we recently engineered monomeric HIV-1 gp120 to bind preferentially b12, a broadly neutralizing antibody to the CD4-binding site (CD4bs) on gp120, by mutating four central residues in the CD4bs to alanine and introducing extra N-glycosylation sites potentially to mask unwanted B-cell epitopes. Despite the favorable antigenicity of this mutant, it harbors two potential caveats that may limit its effectiveness to elicit b12-like antibodies: (i) b12-binding affinity is reduced relative to wild-type gp120 and (ii) binding of some non-neutralizing antibodies to the N-terminal C1 region of gp120 is still observed. Here, we sought to correct these potential limitations. By reverting one of the added N-glycosylation sites on the gp120 core, b12 binding was improved without affecting the epitope-masking properties of the original mutant. Furthermore, truncation of the gp120 N-terminus eliminated binding of the anti-C1 antibodies. Finally, based on the binding profiles of additional non-neutralizing antibodies tested here, further N-glycosylation sites were incorporated to mask their corresponding epitopes. The resulting hyperglycosylated gp120 variants bind b12 and another broadly neutralizing antibody, 2G12, with apparent affinities approaching that of wild-type gp120, but do not bind 21 non- or weakly neutralizing antibodies to seven different epitopes on gp120. These hyperglycosylated variants expand our panel of glycoengineered gp120s that are currently being evaluated for their ability to elicit broadly neutralizing antibodies.

Received October 12, 2004; accepted October 15, 2004.

Edited by James Marks


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
W. Lai, L. Huang, P. Ho, Z. Li, D. Montefiori, and C.-H. Chen
Betulinic Acid Derivatives That Target gp120 and Inhibit Multiple Genetic Subtypes of Human Immunodeficiency Virus Type 1
Antimicrob. Agents Chemother., January 1, 2008; 52(1): 128 - 136.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
A. K. Dhillon, H. Donners, R. Pantophlet, W. E. Johnson, J. M. Decker, G. M. Shaw, F.-H. Lee, D. D. Richman, R. W. Doms, G. Vanham, et al.
Dissecting the Neutralizing Antibody Specificities of Broadly Neutralizing Sera from Human Immunodeficiency Virus Type 1-Infected Donors
J. Virol., June 15, 2007; 81(12): 6548 - 6562.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
W. J. Honnen, C. Krachmarov, S. C. Kayman, M. K. Gorny, S. Zolla-Pazner, and A. Pinter
Type-Specific Epitopes Targeted by Monoclonal Antibodies with Exceptionally Potent Neutralizing Activities for Selected Strains of Human Immunodeficiency Virus Type 1 Map to a Common Region of the V2 Domain of gp120 and Differ Only at Single Positions from the Clade B Consensus Sequence
J. Virol., February 1, 2007; 81(3): 1424 - 1432.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
N. R. Derby, Z. Kraft, E. Kan, E. T. Crooks, S. W. Barnett, I. K. Srivastava, J. M. Binley, and L. Stamatatos
Antibody Responses Elicited in Macaques Immunized with Human Immunodeficiency Virus Type 1 (HIV-1) SF162-Derived gp140 Envelope Immunogens: Comparison with Those Elicited during Homologous Simian/Human Immunodeficiency Virus SHIVSF162P4 and Heterologous HIV-1 Infection.
J. Virol., September 1, 2006; 80(17): 8745 - 8762.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
F. M. Brunel, M. B. Zwick, R. M. F. Cardoso, J. D. Nelson, I. A. Wilson, D. R. Burton, and P. E. Dawson
Structure-Function Analysis of the Epitope for 4E10, a Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody
J. Virol., February 15, 2006; 80(4): 1680 - 1687.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
R. A. Wilkinson, C. Piscitelli, M. Teintze, L. A. Cavacini, M. R. Posner, and C. M. Lawrence
Structure of the Fab Fragment of F105, a Broadly Reactive Anti-Human Immunodeficiency Virus (HIV) Antibody That Recognizes the CD4 Binding Site of HIV Type 1 gp120
J. Virol., October 15, 2005; 79(20): 13060 - 13069.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
S. Selvarajah, B. Puffer, R. Pantophlet, M. Law, R. W. Doms, and D. R. Burton
Comparing Antigenicity and Immunogenicity of Engineered gp120
J. Virol., October 1, 2005; 79(19): 12148 - 12163.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.